Radioactive microspheres with a particle size of 20–45 μm are precisely delivered to solid tumor lesions through minimally invasive procedures. The high energy β radiation emitted during the decay of Yttrium-90 radionuclides kills cancer cells. With an average tissue penetration range of only 2.5 mm, the β radiation minimizes damages to surrounding health tissues.
Yttrium-90 emits high-energy, pure β radiation, and features moderate tissue penetration, a short half-life and limited damage to surrounding healthy tissues, making it well-suited for selective internal radiation therapy (SIRT).
Clinically available activity: 1-13GBq, with personalized production and supply tailored to individual patient needs.
Yttrium-90 is produced using our in-house Strontium-90/Yttrium-90 generator without reliance on the reactor-based irradiation, ensuring a timely and stable supply.
• The page is intended solely to provide technical information and for reference by qualified professionals. For complete and specific information, please refer to the registration certificate and package inserts approved by the relevant regulatory authorities.
• This product should be used strictly in accordance with the approved package inserts and under the guidance of the healthcare professionals.
• The effects of the product may vary depending on individual characteristics, conditions of use and other factors. The information provided on this page does not constitute or should not be construed as any express or implied warranty regarding the product's efficacy or safety.